Recent cancer genome mutation analyses have revealed that GPCRs are mutated in roughly 20% of all malignancies, including mutations in the thyroid hormone receptor (TSHR), the luteinizing hormone receptor (LHCGR), and follicle-stimulating hormone receptor (FSHR) in breast, lung, and colon cancers. This evidence concerns the gene FSHR and colonic neoplasm.